Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Enobosarm: Phase III data

The double-blind, international Phase III POWER1 trial in about 325 patients with stage III or IV NSCLC who were initiating first-line chemotherapy with a platinum agent and taxane showed that once-daily 3 mg

Read the full 339 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE